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Abstract
Background: Intrahepatic recurrence is a significant problem for patients who have undergone a hepatic
resection for hepatocellular carcinoma (HCC). The objective of the present study was to identify risk
factors and evaluate the management of early and late recurrence of solitary HCC after curative resection.
Methods: Included in this study were 816 patients with solitary HCC who underwent a curative partial
hepatectomy. Intrahepatic recurrence in these patients was followed up retrospectively. Prognosis and
therapy for the recurrence were investigated and analysed.
Results: Early and late intrahepatic recurrence occurred in 423 patients and 199 patients, respectively.
Multivariate analysis showed that a tumour diameter >5 cm, the absence of a tumour capsule and the
presence of microvascular invasion were correlated with early recurrence, whereas cirrhosis and alpha-
fetal protein >400 μg/l were independent risk factors contributing to late recurrence. The 5-year survival
of HCC patients with early recurrence was significantly lower than that of patients with late recurrence.
Further curative treatment for intrahepatic recurrence offered a 5-year overall survival of 56.0%, which
was better than alternative management.
Conclusion: Early and late recurrences of solitary HCC after curative resection are associated with
different predictive factors. The time to recurrence and further curative treatment after recurrence were the
best predictors of survival post recurrence.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most frequently
diagnosed cancers and leading causes of cancer-related death
worldwide.1 Surgical treatment options for HCC include PH
(partial hepatectomy) and LT (liver transplantation).2 Theoreti-
cally, LT is the therapeutic gold standard in cirrhotic HCC patients
who meet the Milan criteria because it can remove all the
intrahepatic tumour foci together with the oncogenic cirrhotic
liver.3 Because of the shortage of donor organs and a long waiting
time, primary PH remains the first-line treatment for HCC
patients or serves as a bridge for future salvage LT.4 Unfortunately,
PH is associated with a high risk of post-operative intrahepatic
recurrence that occurs in about 80% of HCC patients at 5 years
and is the leading cause of post-operative death.5–9 Therefore, it is
essential that risk factors of recurrence be determined and a strict
follow-up protocol as well as treatment strategies be established
for early detection and intervention of recurrence.*These authors contributed equally to this work.
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Previous studies reported that early recurrent tumours most
likely originated from subclinical metastasis of primary tumours,
whereas late recurrent tumours might be multicentric or de novo
primary HCC in the remnant liver.10–12 Different risk factors are
considered to be involved in each type of recurrence. Increasing
tumour stage, the presence of microsatellite and microvascular
invasion (MVI) and an elevated alpha-fetoprotein (AFP) level
have been reported to be associated with early recurrence,
whereas cirrhosis, multinodularity and hepatitis activity have
been shown to be predictors of late recurrence.5,10,13 However, in
most of these studies, the enrolled patients were heterogeneous
in terms of clinicopathological characteristics and management-
related factors. Various studies have produced conflicting results
concerning factors predicting recurrence, and few previous
studies have focused on risk factors for intrahepatic recurrence
in an exclusive cohort of patients with solitary HCC after cura-
tive PH.
The aim of this study was to identify prognostic factors influ-
encing post-operative recurrence and survival of patients under-
going curative PH for solitary HCC.
Materials and methods
Enrolled in this study were 918 consecutive patients who had
undergone curative PH for solitary HCC at the Eastern
Hepatobiliary Surgery Hospital (Shanghai, China) betweenMarch
2000 and September 2010. The pre-operative clinical diagnosis of
HCC was consistent with the diagnostic criteria of the American
Association for the Study of Liver Diseases (AASLD).14 Patients
who met the following criteria were included this study: pre-
operative World Health Organization performance status of 0–1;
Child–Pugh class A; only one hepatic lesion; no extrahepatic
metastases; no image-visualizable tumour thrombus in the portal
vein, hepatic vein or bile duct branches; and suitable for curative
PH.
The surgical strategy for HCC was standardized for all patients.
Curative resection of HCC was performed as described previ-
ously.15 In brief, the whole tumour was resected with a negative
surgical margin confirmed by histological examination; the pre-
operative elevated AFP level decreased to the normal range within
2 months after surgery; and no new image-visualizable intra- and
extrahepatic lesions within 2 months after surgery. Patients who
underwent palliative resection and/or adjuvant therapy after a
hepatectomy, or died owing to severe complications within 1
month after surgery were excluded from this study. This study was
approved by the Institutional Review Board of the Eastern
Hepatobiliary Surgery Hospital.
The diagnosis of HCC was confirmed in all patients by
pathological evaluation of the surgically resected specimens. The
histological grade of tumour differentiation was assigned by the
Edmondson–Steiner’s classification system.
Clinicopathological factors that were potentially related to
recurrence included age, gender (male or female), serum hepa-
titis B surface antigen (HBsAg) status (positive or negative),
hepatitis E surface antigen (HBeAg) status (positive or negative),
cirrhosis (presence or absence), AFP level (≤400 or >400 μg/l),
prothrombin time (PT) (≤13 or >13 s), platelet count (PLT)
(≤100 or >100 × 109/l), total bilirubin (TBIL) (≤17.1 or
>17.1 μmol/l), albumin (ALB) (≤35 or >35 g/l), alanine
aminotransferase (ALT) (≤50 or >50 U/l), hepatitis B virus
(HBV)-DNA (≤4 or >4 l g, IU/ml), intra-operative blood trans-
fusion (yes or no), surgical margin (<2 or ≥2 cm), anatomical
PH (yes or no), tumour diameter (≤5 or >5 cm), tumour capsule
(yes or no), MVI (yes or no), and Edmondson–Steiner’s classi-
fication (I/II or III/IV).
All patients were followed up regularly every 2 months during
the first 2 years, and 3 months afterwards, and monitored by a
standard protocol including serum AFP, immunological indexes
of HBV, liver function, abdominal ultrasound or contrast-
enhanced computerized tomography (CT)/magnetic resonance
imaging (MRI) and chest X-ray. All patients were followed up
until September 2013.
Once recurrence was suspected based on the combined results
of these clinical examinations, patients were hospitalized and
treated with curative treatments including re-resection, percuta-
neous ethanol injection (PEI) or radiofrequency ablation
(RFA) when the recurrence was localized, or otherwise with
transcatheter arterial chemoembolization (TACE) or conserva-
tive management with sorafenib when the recurrence was diffuse.
Time to recurrence (TTR) was defined as the period between
surgery and the diagnosis of recurrence by setting 2 years as the
cut-off between the early and late recurrences.5,13,16 The overall
survival (OS) time was defined as the interval between PH and
death or between PH and the last follow-up. Patients who died
for reasons not related to HCC were censored at the time of
death.
Statistical analysis
Continuous variables were reported as the median and range,
The cut-off values of the continuous variables were based on
those used commonly in previous studies or as determined by
maximizing the Youden’s index, i.e. sensitivity + specificity-1, as
calculated from the receiver-operating characteristic curve
(ROC).17 The χ2 test or Fisher’s exact probability test was used
for categorical variables. The cumulative survival time was cal-
culated using the Kaplan–Meier method and compared by the
log-rank test. The Cox proportional hazards model was used to
determine independent factors of recurrence based on the vari-
ables selected by univariate analysis. All the significant predictors
of recurrence in the univariate analysis were analysed in a logis-
tic regression model to show an independent value at the mul-
tivariate analysis. Statistical analyses were performed by SAS
9.1.3 software (SAS Institute Inc., Cary, NC) and R 2.13.2
(http://www.r-project.org/). A two-tailed value of P < 0.05 was
considered statistically significant.
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Results
Of the 918 patients 102 (11.1%) patients were excluded.
The median follow-up time was 53 (18–104) months; the
median OS time was 62 months; and the 1-, 3- and 5-year recur-
rence and OS of these patients was 25%, 64%, 75%, 90%, 65% and
51%, respectively. Of the 816 patients in this series, 622 (76%)
patients developed intrahepatic recurrence, of whom 423 (423/
622, 68%) patients experienced recurrences within the first 2 years
(early recurrence) and 199 (199/622, 32%) after 2 years (late
recurrence). In the non-recurrence group, the 5-year OS was 85%
versus 38% for all patients who recurred (P < 0.001). The 5-year
OS in the late recurrence group was significantly higher than that
in the early recurrence group (59% versus 28%, P < 0.001)
(Fig. 1).
Univariate and multivariate analysis of risk factors for both
early and late recurrence are shown in Tables 1 and 2.
Therapy and prognosis after recurrence
Of the 423 patients in the early intrahepatic recurrence group,
further curative treatment was performed in 135 (32%) patients,
including re-resection (n = 97, 23%), PEI (n = 13, 3%) and RFA (n
= 25, 6%). Of the 199 patients in the late intrahepatic recurrence
group, further curative treatment was indicated in 91 (46%,
P = 0.039) patients, including re-resection (n = 61, 31%), PEI
(n = 9, 5%) and RFA (n = 21, 10%).
After recurrence, the 1-, 3- and 5-year OS of the 236
patients who received further curative treatment was significant
greater than the 393 patients who did not receive further
curative treatment (96%, 70% and 56% versus 82%, 47% and
28%, P < 0.001). Furthermore, The 1-, 3- and 5-year OS of
patients who received TACE for recurrence was significant better
than that of patients who received conservative management
with Sorafenib after recurrence (86%, 51% and 34% versus 69%,
35% and 9%, P < 0.001), but lower than that of patients who
received further surgical curative treatment for recurrence
(P = 0.030). There were no significant differences in OS among
the patients who received re-resection, RFA and PEI after
recurrence.
Discussion
In the present study, risk factors and management for early and
late recurrence of solitary HCC based on a large cohort of patients
who underwent curative PH were assessed. The results show that
early recurrence is a major problem after curative PH even in
patients with solitary HCC.
Previous studies13,18 suggest that intrahepatic metastases are the
main cause of early intrahepatic recurrence. In the present study,
results confirmed that early was associated with adverse tumour
factors, such as larger tumour size, MVI and the absence of a
tumour capsule, as reported previously.19–21 The high early recur-
rence rates seen in HCC patients with these characteristics suggest
that there may be microscopic intrahepatic dissemination beyond
the resection field in such patients and therefore simple tumour
removal would seem insufficient.22
Liver cirrhosis has been considered to be the only risk factor
related to late recurrence in patients with HCC after PH.13,16
Cucchetti et al.11 reported that the risk factors for late recurrence
in cirrhotic HCC patients are the same as for HCC occurrence in
the general cirrhotic population, confirming the hypothesis that
late recurrence is to be considered multicentric HCC. In this
study, cirrhosis was also identified as one of the risk factors con-
tributing to late recurrence. However, a high pre-operative serum
AFP level was also associated with late recurrence. Even without
cirrhosis, HCC is prone to recurrence 2 years after PH when the
serum AFP level was >400 μg/l.
An alternative interpretation of the current results is the asso-
ciation of cirrhosis and AFP. Previous studies reported that AFP
could be used as a marker for liver fibrosis.23,24 AFP values were
above the normal limit in 20–60% patients with liver cirrhosis
even in the absence of HCC.25 Liver cirrhosis is however more
common in AFP-positive patients.26 Cirrhotic patients with high
AFP levels were more susceptible to develop HCC.11 The above
findings indicate that there is some underlying relationship
between cirrhosis and AFP that influences the carcinogenesis of
HCC. The present studies results would suggest that cirrhotic
patients with an AFP level >400 μg/l should be closely followed up
beyond 2 years.
1.0
0.8
0.6
0.4
0.2
0.0
0 1 2 3 4 5
Number at risk survival time (years)
Cu
m
ul
at
ive
 s
ur
viv
al
 ra
te
Early
Late
423
199
365
199
257
199
133
172
74
129
35
85
11
51
9
36
6
26
0
26
0
26
6 7
Early recurrence
Late recurrence
P < 0.001
8 9 10
Figure 1 Long-term survival from the diagnosis of intrahepatic recur-
rence according to time of presentation (earlier or later than 2 years)
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Further attempts at curative treatment including re-resection,
RFA and PEI have been shown to be effective treatments for
recurrent HCC, offering a cumulative 5-year survival rate ranging
from 40% to 64%.16,27 Although similar outcomes were achieved
within the present study, only 32% of patients with early recur-
rence and 46% of patients with late recurrence were suitable for
such approaches. It has been suggested that salvage liver trans-
plantation (SLT) is an efficacious treatment for patients with
Table 1 Univariate analysis of factors associated with early and late recurrence
Variable No recurrence
(n = 194)
Early recurrence
(n = 423)
P* Late recurrence
(n = 199)
P**
Median age (range. years) 52 (23–79) 51 (16–79) 0.179 51 (16–73) 0.854
Follow-up time (range. months) 63 (28–104) 45 (18–104) 0.017 58 (25–104) 0.004
Gender Male 172 371 0.735 173 0.602
Female 22 52 26
HBsAg Positive 164 356 0.905 178 0.15
Negative 30 67 21
HBeAg Positive 81 175 0.929 67 0.098
Negative 113 248 132
Cirrhosis Presence 133 329 0.014 163 0.002
Absence 61 94 36
AFP (ug/l) ≤400 146 279 0.021 113 <0.001
>400 48 144 86
PT (s) ≤13 101 242 0.232 100 0.720
>13 93 181 99
PLT (109/l) ≤100 42 73 0.194 53 0.249
>100 152 350 146
TBIL (μmol/l) ≤17.1 134 303 0.516 145 0.408
>17.1 60 120 54
ALB (g/l) ≤35 10 24 0.793 15 0.336
>35 184 399 184
ALT (U/l) ≤50 132 261 0.129 130 0.568
>50 62 162 69
HBV-DNA (l g, IU/ml) ≤4 127 261 0.369 148 0.055
>4 67 162 51
Intra-operative blood transfusion Yes 24 75 0.094 17 0.217
No 170 348 182
Surgical margin (cm) <2 57 163 0.028 78 0.041
≥2 137 260 121
Anatomical hepatectomy Yes 113 273 0.134 130 0.149
No 81 150 69
Tumour diameter (cm) ≤5 144 257 0.001 129 0.043
>5 50 166 70
Tumour capsule Complete 119 191 <0.001 101 0.035
Incomplete 75 232 98
MVI Presence 80 251 <0.001 104 0.028
Absence 114 172 95
Edmondson–Steiner classification I.II 122 230 0.048 109 0.103
III.IV 72 193 90
*Logistic regression analysis was performed on parameters between patients with early recurrence and patients with no recurrence.
**Logistic regression analysis was performed on parameters between patients with late recurrence and patients with no recurrence.
AFP, alpha-fetoprotein; ALB, albumin; ALT, alanine aminotransferase; HBeAg, hepatitis e antigen; HBsAg, hepatitis B surface antigen; HBV-DNA,
hepatitis B virus-deoxyribonucleic acid; MVI, microvascular invasion; PLT, platelet; PT, prothrombin time; TBIL, total bilirubin.
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recurrent HCC and should be considered when re-resection is not
feasible.28,29 However, this optimistic suggestion needs to be
further confirmed by an analysis of clinical outcomes. In the
current study, no patients undergo SLT for recurrent HCC owing
to the scarcity of donors or long waiting time, and the majority of
patients with recurrence received TACE or conservative treatment
with sorafenib.
In conclusion, the present study suggests that early and late
intrahepatic recurrences of solitary HCC after curative PH have
distinct factors, and the pattern of recurrence and the probability
of curative treatments after recurrence are the best determinants
for the prognosis. The strength of this study lies in the relative
large sample size involving 816 patients with solitary HCC
tumours who underwent curative resection.
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